In patients with moderate to severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m²) or on chronic dialysis, should ticagrelor or clopidogrel be used as the antiplatelet therapy?

Clopidogrel is Preferred Over Ticagrelor in Severe Renal Impairment

In patients with moderate to severe renal impairment (eGFR <30 mL/min/1.73 m²) or on chronic dialysis requiring antiplatelet therapy, clopidogrel should be used rather than ticagrelor due to significantly increased bleeding risk with ticagrelor without proven efficacy benefit in this population.

Evidence-Based Rationale

FDA Label Guidance on Renal Impairment

The clopidogrel FDA label explicitly states that experience is limited in patients with severe and moderate renal impairment, but no dosage adjustment is necessary 1. Importantly, pharmacodynamic data show that patients with severe renal impairment (creatinine clearance 5-15 mL/min) and moderate renal impairment (creatinine clearance 30-60 mL/min) demonstrated only 25% inhibition of ADP-induced platelet aggregation with standard 75 mg daily dosing 1. While this represents reduced efficacy, the drug remains usable without dose modification.

Critical Safety Signal: Increased Bleeding with Ticagrelor

The most compelling evidence comes from a 2022 Chinese study of 276 patients with ACS and severe renal insufficiency (eGFR ≤30 ml/min or dialysis) undergoing PCI. Ticagrelor significantly increased total bleeding risk (HR 3.01; 95% CI 1.81-5.62; p=0.01) compared to clopidogrel, without improving major adverse cardiovascular events or all-cause mortality 2. This represents a clear harm without benefit.

Lack of Efficacy Advantage in Severe Renal Disease

Multiple studies demonstrate no efficacy benefit for ticagrelor in severe renal impairment:

• A 2023 meta-analysis of five observational studies in ESKD patients on dialysis found no significant difference between ticagrelor and clopidogrel in composite efficacy outcomes (p=0.40), all-cause mortality (p=0.82), cardiovascular mortality (p=0.79), or stroke risk (p=0.21) 3

• A 2025 Taiwanese registry study of patients with diabetes, ACS, and CKD showed ticagrelor was associated with increased myocardial infarction (HR 1.59), CV-related readmission (HR 1.72), and repeated revascularization (HR 2.24) compared to clopidogrel 4

• A 2026 Korean multicenter registry of 7,590 AMI patients with renal impairment found no significant differences in MACCE (HR 0.810; p=0.212) or bleeding between initial ticagrelor versus clopidogrel strategies after propensity matching 5

Bleeding Risk Gradient by Renal Function

The 2018 Swedish registry analysis of 45,206 MI patients demonstrated that while ticagrelor showed efficacy benefits in patients with eGFR >30, bleeding events were substantially more abundant in patients with eGFR <30 (HR 1.79; 95% CI 1.00-3.21) 6. This bleeding risk increases as renal function declines, with the most severe impairment showing the highest risk.

Pharmacodynamic Considerations

A 2026 study directly comparing platelet reactivity showed that CKD significantly impairs clopidogrel responsiveness but does not affect ticagrelor 7. While this might suggest ticagrelor superiority, the clinical outcome data clearly demonstrate this pharmacodynamic advantage does not translate to improved clinical outcomes in severe renal impairment, while bleeding risk remains elevated.

Clinical Algorithm

For eGFR <30 mL/min/1.73 m² or dialysis patients:

1. Use clopidogrel 75 mg daily as first-line P2Y12 inhibitor
2. No dose adjustment required despite reduced platelet inhibition 1
3. Avoid ticagrelor due to 3-fold increased bleeding risk without efficacy benefit 2
4. Consider aspirin dose optimization (lowest effective dose) to minimize bleeding
5. Implement strict gastroprotection with proton pump inhibitors (avoid omeprazole/esomeprazole with clopidogrel; use pantoprazole, lansoprazole, or dexlansoprazole) 1

For eGFR 30-60 mL/min/1.73 m²:

1. Either clopidogrel or ticagrelor may be used based on individual bleeding risk assessment
2. Clopidogrel remains safer option if bleeding risk is elevated
3. Ticagrelor may be considered if ischemic risk substantially outweighs bleeding risk

Critical Pitfalls to Avoid

• Do not assume ticagrelor superiority from general ACS trials applies to severe renal impairment - the PLATO trial excluded patients with creatinine clearance <30 mL/min
• Do not overlook the 3-fold bleeding increase with ticagrelor in severe renal impairment 2
• Do not use omeprazole or esomeprazole with clopidogrel - these significantly reduce clopidogrel's antiplatelet activity 1
• Monitor for bleeding complications closely - both agents increase bleeding risk, but ticagrelor substantially more so in severe CKD
• Recognize that many patients initially started on ticagrelor are switched to clopidogrel in real-world practice, likely due to tolerability and bleeding concerns 5

The evidence consistently demonstrates that in severe renal impairment, the bleeding risk of ticagrelor outweighs any theoretical platelet inhibition advantage, making clopidogrel the safer and equally effective choice.